CurrentAmbetter NevadaPolicy CP.MP.154

Thyroid Hormones and Insulin Testing in Pediatrics

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.154 alerts

Get alerted when Policy CP.MP.154 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity and coding guidance for thyroid (TSH, T3, T4) and insulin laboratory testing in children aged 1–18, with guidance for health plans affiliated with Centene Corporation including Ambetter Nevada.

Policy Summary

PayerAmbetter Nevada

PolicyThyroid Hormones and Insulin Testing in Pediatrics

Policy CodePolicy CP.MP.154

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionAvoid routine thyroid and insulin testing in otherwise healthy children age 1–18; ensure appropriate coding and documentation before submission to prevent denials.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1–18age range

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmbetter NevadaPolicy CP.MP.154

Thyroid Hormones and Insulin Testing in Pediatrics

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.154 alerts

Get alerted when Policy CP.MP.154 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmbetter Nevada

PolicyThyroid Hormones and Insulin Testing in Pediatrics

Policy CodePolicy CP.MP.154

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionAvoid routine thyroid and insulin testing in otherwise healthy children age 1–18; ensure appropriate coding and documentation before submission to prevent denials.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1–18age range

9 codesCPT not medically necessary

Coverage Criteria for Thyroid Hormone and Insulin Testing (Pediatrics)

Not medically necessary: routine thyroid and insulin testing in otherwise healthy pediatric patients

Not medically necessary statements

I. Thyroid testing: Routine thyroid hormone testing in healthy, including obese but otherwise healthy, children (age ≥ 1 and ≤ 18) is not medically necessary because these tests have not been demonstrated to have a clear clinical benefit.

From policy criteria I

II. Insulin testing: Routine insulin testing in healthy, including obese but otherwise healthy, children (age ≥ 1 and ≤ 18) is not medically necessary because these tests have not been demonstrated to have a clear clinical benefit.

From policy criteria II

The policy aligns with guideline recommendations that clinicians should not perform routine endocrine laboratory evaluations when assessing pediatric obesity unless specific clinical features suggest an endocrine cause. In particular, routine testing for thyroid or insulin abnormalities is discouraged unless there is evidence of attenuated stature or reduced height velocity, or other clinical findings that would warrant targeted evaluation.

Routine laboratory testing of thyroid hormones and insulin in otherwise healthy children (including those who are obese but without other concerning clinical signs) is not medically necessary for children age ≥ 1 and ≤ 18. CPT codes listed in Table 1 (for insulin and thyroid testing) are identified as not medically necessary when submitted with the obesity/encounter/BMI diagnosis codes listed in Table 2; providers should confirm medical necessity and appropriate diagnosis coding before submitting claims to avoid denial.

Coding Guidance and Tables

CPT codes not medically necessary when billed with corresponding ICD-10-CM in Table 2CPTNot Covered

83525	Insulin; total.
83527	Insulin; free.
84436	Thyroxine; total.
84439	Thyroxine; free.
84443	Thyroid stimulating hormone (TSH).
84479	Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR).
84480	Triiodothyronine T3; total (TT-3).
84481	Triiodothyronine T3; free.
84482	Triiodothyronine T3; reverse.

ICD-10-CM diagnosis codes not medically necessary when billed with corresponding CPT codes in Table 1ICD-10Not Covered

E66.01	Morbid (severe) obesity due to excess calories.
E66.09	Other obesity due to excess calories.
E66.1	Drug-induced obesity.
E66.3	Overweight.
E66.8	Other obesity.
E66.9	Obesity, unspecified.
Z00.00	Encounter for general adult medical examination without abnormal findings.
Z00.129	Encounter for routine child health examination without abnormal findings.
Z00.8	Encounter for other general examination.
Z68.52	Body mass index [BMI] pediatric, 5th percentile to less than 85th percentile for age.

1–10 of 12

1/2

Provider Actions, Billing and Denial Risk

Billing Rule

Not medically necessary CPTs when billed with listed ICD-10s — verify coding before submission

The CPT codes listed in Table 1 (83525, 83527, 84436, 84439, 84443, 84479, 84480, 84481, 84482) are designated as not medically necessary when billed with the corresponding ICD-10-CM diagnosis codes in Table 2; providers should verify coding and medical necessity documentation before submission to avoid claim denials.

Affected CPTs: 83525, 83527, 84436, 84439, 84443, 84479, 84480, 84481, 84482
Affected ICD-10s: E66.01, E66.09, E66.1, E66.3, E66.8, E66.9, Z00.00, Z00.129, Z00.8, Z68.52, Z68.53, Z68.54

Prior Authorization

Do not order routine thyroid or insulin tests for otherwise healthy pediatric patients

Background

Thyroid hormones (T4 and T3) regulate many metabolic processes through the hypothalamic–pituitary–thyroid feedback loop, with thyroxine (T4) as the major secreted hormone and thyroid stimulating hormone (TSH) from the pituitary controlling T4 secretion. Disruption of this regulatory cycle can result in hyperthyroidism or primary/secondary hypothyroidism. In pediatric practice, TSH and total T4 may be elevated in some children who are overweight or obese, but current evidence does not establish a causal relationship; measuring insulin concentrations to diagnose insulin resistance is limited by assay variability, lack of standardized cut points, and poor reproducibility, so fasting insulin remains a research measure without clinical diagnostic value.

Definitions

inv-11: Thyroxine (T4) — definition and regulatory context

DefinitionThyroxine (T4) is the major secretory hormone of the thyroid (contains four iodine atoms) and is converted to triiodothyronine (T3).

RegulationSecretion of T4 is regulated by thyroid stimulating hormone (TSH) via the hypothalamic–pituitary–thyroid feedback loop.

Clinical context in pediatricsTSH and total T4 may be elevated in children who are overweight or obese, but it is unclear whether this is causal; routine screening in otherwise healthy children has not been shown to provide actionable clinical information.

Role in assessmentQuantification of T4 (total or free) can be used to assess thyroid function when clinically indicated rather than for routine screening.

inv-12: TSH — definition and use in assessment of thyroid function

Definition

Policy Summary

PayerAmbetter Nevada

PolicyThyroid Hormones and Insulin Testing in Pediatrics

Policy CodePolicy CP.MP.154

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionAvoid routine thyroid and insulin testing in otherwise healthy children age 1–18; ensure appropriate coding and documentation before submission to prevent denials.

SourceLink

On This Page

Routine thyroid hormone testing and routine insulin testing in otherwise healthy children (age ≥1 and ≤18) are expressly identified as not medically necessary by the policy; providers must not rely on screening/obesity encounter codes alone to justify these tests.

Policy statement I: routine thyroid hormone testing in healthy (including obese but otherwise healthy) children age ≥1 and ≤18 is not medically necessary.
Policy statement II: routine insulin testing in healthy (including obese but otherwise healthy) children age ≥1 and ≤18 is not medically necessary.

Documentation Required

Claims documentation: include clinical justification when submitting listed CPTs with obesity/BMI or routine exam ICD-10s

When the CPT codes in Table 1 (83525, 83527, 84436, 84439, 84443, 84479, 84480, 84481, 84482) are submitted with ICD-10-CM codes for obesity, routine exam, or pediatric BMI codes listed in Table 2, claims are identified as not medically necessary per the policy and should include documentation justifying medical necessity if clinically appropriate.

Document clinical indications beyond routine obesity or well-child encounter codes (Table 2) if testing is clinically indicated.
Include relevant exam findings (e.g., attenuated stature or decreased height velocity) that support deviation from the policy’s routine-testing exclusion.

Denial Risk

Denial risk: routine endocrine testing in healthy pediatric patients

Claims for the CPTs listed in Table 1 may be denied when submitted for routine testing in otherwise healthy pediatric patients (age 1–18); denials are particularly likely when those CPTs are billed with the Table 2 ICD-10s (obesity, routine exam, pediatric BMI) without additional clinical justification.

Denial risk applies to routine thyroid hormone and routine insulin testing in healthy children age ≥1 and ≤18.
Denials are likely when CPTs 83525, 83527, 84436, 84439, 84443, 84479, 84480, 84481, 84482 are paired with Table 2 ICD-10 codes without supporting documentation.

Thyroid stimulating hormone (TSH) is produced by the pituitary gland and regulates thyroid hormone secretion as part of the hypothalamic–pituitary–thyroid axis.

Use in assessmentTSH measurement is used to assess thyroid function through its feedback relationship with T4 and T3; abnormal TSH may indicate primary or secondary thyroid dysfunction.

Pediatric considerationsElevations in TSH (and total T4) can be observed in overweight or obese children; because causality is unclear, routine TSH screening in otherwise healthy pediatric patients is not supported.

inv-13: Fasting insulin testing — definition and policy stance that it's a research tool without clinical value for routine screening

DefinitionFasting insulin testing measures plasma insulin concentration (typically after a fast).

Assay limitationsThere is a lack of standardized insulin assays and poor reproducibility, including cross-reactivity with proinsulin and race/ethnicity–related differences in insulin concentrations.

Diagnostic utilityFasting insulin shows considerable overlap between insulin-resistant and insulin-sensitive youths and there is no well-defined cut point to differentiate normal from abnormal; therefore it lacks a universally accepted, clinically useful threshold.

Policy stanceMeasuring plasma (fasting) insulin concentrations is considered a research tool with no clinical value for evaluating insulin resistance in pediatric obesity and is not recommended for routine screening.